(Q43782311)

26 November 2017

title

Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa (English)

1 reference

26 November 2017

K Geboes

1

1 reference

26 November 2017

W Dekker

2

1 reference

26 November 2017

C J Mulder

3

1 reference

26 November 2017

K Nusteling

4

1 reference

26 November 2017

Dutch Study Group

5

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

Alimentary Pharmacology & Therapeutics

26 November 2017

published in

1 reference

26 November 2017

volume

15

1 reference

26 November 2017

issue

11

1 reference

26 November 2017

page(s)

1819-1826

1 reference

Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons.

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01105.X

Intestinal metaplasia and Helicobacter pylori: an endoscopic bioptic study of the gastric antrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01105.X

Long-term sequelae of Helicobacter pylori gastritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01105.X

Helicobacter pylori infection and the risk of gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01105.X

Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01105.X

Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01105.X

Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01105.X

The Sydney System: a new classification of gastritis. Introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01105.X

Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01105.X

Interobserver variability in application of the revised Sydney classification for gastritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01105.X

Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01105.X

Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01105.X

Long-term follow-up of gastric histology after Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01105.X

10.1046/J.1365-2036.2001.01105.X

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference